Business
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical
About this update from Caribou Biosciences, Inc.
[{"type":"text","content":"BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences: • Caribou’s webcast of KOL discussion from 2024 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2024, CB-010 ANTLER Phase 1 clinical trial data in r/r B-NHL to be shared in a press release at 6:00 pm CDT followed by a live webcast of a discussion with KOLs and management at 7:00 pm CDT. The presenters will include: Boyu Hu, MD, director of lymphoma and CLL in the division of hematology and hematologic malignancies, University of UtahMehdi Hamadani, MD, professor of medicine, section chief of hematologic malignancies, Medical College of WisconsinRachel Haurwitz, PhD, president and chief executive officer, Caribou Biosciences Additional participants from Caribou Biosciences include: Steve Kanner, PhD, chief scientific officerJason O’Byrne, chief financial officerKike Zudaire, PhD, senior vice president, translational sciences and therapeutic discoveryTonia Nesheiwat, PharmD, vice president of medical affairs and project leadership • Jefferies Global Healthcare Conference, New York, NYJune 5, 2024, corporate presentation at 3:00 pm EDTWebcast • Goldman Sachs 45th Annual Global Healthcare Conference, Miami, FLJune 12, 2024, fireside chat at 8:00 am EDTWebcast For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event. About Caribou’s novel next-generation CRISPR platformCRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou ...